Details of the Drug

General Information of Drug (ID: DMH9GWW)

Drug Name
DSG3-CAART
Indication
Disease Entry ICD 11 Status REF
Pemphigus vulgaris EB40 Phase 1 [1]
Drug Type
CAR-T cell therapy
Cross-matching ID
TTD ID
DE1XF0

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Desmoglein-3 (DSG3) TTEO4P8 DSG3_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04422912) A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris. U.S.National Institutes of Health.
2 Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020 Dec 1;130(12):6317-6324.